Clinical trials: Histological Response
Colitis, Ulcerative
Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).
The purpose of this study is to evaluate serum soluble human ST2 protein, the receptor for Interleukin-33 (IL-33) and a member of the proinflammatory Interleukin-1 (IL-1) receptor superfamily, as a surrogate biological marker…
- Trial name
- EVOLUTION (NCT02318667)
- Testing
- Golimumab
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma
This is an open randomised phase II study evaluating the anti-tumour activity, safety and pharmacology of two dose regimens of IPH2101, a human monoclonal anti-KIR antibody, in patients with multiple myeloma in stable partial…
- Trial name
- REMYKIR (NCT00999830)
- Testing
- IPH2101
- Where
- 9 sites in France
- Volunteers
- 27 people
- Sponsor
- Innate Pharma
Eosinophilic Esophagitis (EoE)
A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved
A study in adolescents and adults with eosinophilic esophagitis (EoE) to measure the histologic response and determine if any reduction in dysphagia is achieved.
- Trial name
- NCT02605837
- Testing
- Oral Budesonide Suspension (OBS)
- Where
- 77 sites in United States
- Volunteers
- 318 people
- Sponsor
- Shire
Diffuse Large B Cell Lymphoma
18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma
Open-label, multicenter, uncontrolled and non-randomized study comparing 18F-FDG PET-Scan and diffusion MRI in the assessment of the early therapeutic response of Diffuse Large B-Cell Lymphoma.
- Trial name
- LYMPHODTECT (NCT03121456)
- Testing
- 18F-FDG PET SCAN, MRI DIFFUSION
- Where
- France
- Volunteers
- 74 people
- Sponsor
- Centre Antoine Lacassagne
Bladder Cancer
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
In this study, the investigators would like to assess how intravesical BCG schedules after immunization of non muscle invasive bladder patients with the recMAGE-A3 protein, together with adjuvant AS15 (recMAGE-A3 + AS15 ASCI)…
- Trial name
- NCT01498172
- Testing
- MAGE-A3 ASCI, BCG
- Where
- Switzerland
- Volunteers
- 23 people
- Sponsor
- Patrice Jichlinski
Prostate Cancer, Breast Cancer
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
This study is a retrospective one, exploring the hypothesis that a person's genotypic makeup may be associated with a clinical response or toxic effect to a drug.
- Conditions
- Prostate Cancer, Breast Cancer, Cutaneous T-Cell Lymphoma, Lung Cancer
- Trial name
- NCT00341939
- Where
- United States
- Volunteers
- 484 people
- Sponsor
- National Cancer Institute (NCI)
Intrahepatic Cholangiocarcinoma
Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
This phase II trial tests whether contrast-enhanced ultrasound can predict the response of bile duct cancer to targeted radiotherapy (radioembolization treatment).
- Trial name
- NCT05328167
- Testing
- Perflutren Protein-Type A Microspheres, Contrast-Enhanced Ultrasound
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Thomas Jefferson University
Melanoma, Cancer
BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs
BLOOD is an investigator-initiated, multicenter, prospective biomarker study in patients with advanced melanoma treated with anti-PD-1 monotherapy in the first-line setting.
- Trial name
- BLOOD (NCT04473027)
- Testing
- Blood sample collection
- Where
- Belgium
- Volunteers
- 3 people
- Sponsor
- University Hospital, Ghent
Sarcoma
Monitoring Chemotherapy Response of Soft Tissue Sarcomas and Osteosarcomas Using Diffuse Optical Spectroscopic Imaging
The purpose of this study is to determine the ability of a specific imaging method, termed Diffuse Optical Spectroscopic Imaging, to provide metabolic and functional information which can be used to predict overall response to…
- Trial name
- NCT01263405
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Kidney Transplant, Myeloma
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
The primary endpoint of this study is to compare the humoral response (titre and neutralizing capacity of induced antibodies) against SARS-CoV-2 following vaccination with BNT162b2 (Pfizer BioNTech) in immunocompromised persons…
- Conditions
- Kidney Transplant, Myeloma, Cancer, Hematologic Malignancy
- Trial name
- EREVA (NCT04952766)
- Testing
- Biological samples
- Where
- France
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Régional d'Orléans
Melanoma
IL2 Imaging in Metastatic Melanoma
T cell infiltration of tumor lesions is a known prognostic factor in several tumor types and is used as treatment mechanism in some of these tumor types.
- Trial name
- NCT02922283
- Testing
- IL2-PET scan, Tumor biopsy, CT scan
- Where
- Netherlands
- Volunteers
- 19 people
- Sponsor
- University Medical Center Groningen
Chronic Lymphocytic Leukemia
Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy
This study explores the potential to improve the quality of response obtained after induction treatment in Chronic Lymphocytic Leukemia (CLL), by giving a short and intense consolidation schema using high-dose rituximab.
- Trial name
- HYDRIC (NCT01625741)
- Testing
- Rituximab
- Where
- 15 sites in Belgium
- Volunteers
- 6 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Leukemia, Other, Cancer
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
1.0 OBJECTIVES 1.1 To test the activity of arsenic trioxide in combination with imatinib in patients with CML with cytogenetic evidence of residual disease. 1.2 To determine the toxicity associated with this therapy.
- Trial name
- NCT00250042
- Testing
- Gleevec and Arsenic Trioxide
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- New Mexico Cancer Research Alliance
Kidney Cancer
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
The goal of this clinical research study is to compare pazopanib to temsirolimus in the treatment of advanced clear-cell renal cell carcinoma. The safety of each drug will also be studied.
- Trial name
- NCT01392183
- Testing
- Pazopanib, Temsirolimus, Quality of Life Assessment
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
NSCLC, Melanoma
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
Immunotherapy with agents stimulating the immune system to act against cancer are now a new standard of care in various cancers as lung cancer and melanoma, but also bladder cancer, kidney cancer and head \& neck cancer.
- Conditions
- NSCLC, Melanoma, Kidney Cancer, Urothelial Carcinoma
- Trial name
- NCT04146064
- Testing
- Breathprint analysis and patient-reported outcomes
- Where
- Canada
- Volunteers
- 190 people
- Sponsor
- University Health Network, Toronto
Multiple Myeloma
Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma
The study involves the use of a targeted form of radiation, in addition to standard high dose chemotherapy and stem cell transplant for multiple myeloma.
- Trial name
- NCT01207765
- Testing
- indium-111-ibritumomab tiuxetan, 90Y Zevalin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Tufts Medical Center
Myeloma
Machine Learning in Myeloma Response
Diffusion-weighted Whole Body Magnetic Resonance Imaging (WB-MRI) is a new technique that builds on existing Magnetic Resonance Imaging (MRI) technology.
- Trial name
- MALIMAR (NCT03574454)
- Testing
- Machine Learning (ML)
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Hepatocellular Carcinoma, Liver Cancer
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
Background: Primary Liver Cancer is the second most common cause of cancer-related death worldwide. It is the cancer with the fastest rising incidence and mortality in the United States.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Cholangiocarcinoma
- Trial name
- NCT04145141
- Where
- 4 sites in United States
- Volunteers
- 132 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Lymphoma
A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma
The purpose of this study is to test how safe and effective the research study drug, pembrolizumab is as a treatment for patients with Hodgkin lymphoma who have not previously been treated for this disease and are unsuitable for…
- Trial name
- PLIMATH (NCT03331731)
- Testing
- pembrolizumab
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 27 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.